Sudden cardiac death is preventable with implantable cardioverterdefibrillators. These devices can now be placed not only in patients who have had a sustained arrhythmia, but also in those deemed high risk for whom a mortality benefit can also be derived. Unfortunately, a sizable percentage of patients who receive these devices may have frequent or inappropriate shock therapy. We have learned that these events are psychologically devastating, cause frequent hospitalizations, and predispose to morbid and mortal events. Although antiarrhythmic drugs are frequently used to prevent frequent device discharges, no drug has gained US regulatory approval for this indication. On the basis of favorable data obtained in a small phase IIA trial, we studied the efficacy and safety of celivarone, a novel benzofuran derivative and congener of amiodarone and dronedarone, for the prevention of device activation and sudden death. In a multinational, multicenter, prospective, double-blind, randomized parallel-group trial, we compared 3 doses of celivarone with placebo and included an amiodarone calibrator arm to confirm the adequacy of the design and the study population. Although it proved to be well tolerated and safe, we found no significant benefit for celivarone for this indication at any dose. Amiodarone, as expected, reduced device activations, including shocks, but was associated with a higher mortality than placebo, whereas celivarone was mortality neutral. The search for drugs to prevent device activation and death in implantable cardioverter-defibrillator patients will continue. The Dose Ranging Study of Celivarone With Amiodarone as Calibrator for the Prevention of Implantable Cardioverter Defibrillator Interventions or Death (ALPHEE), although a negative trial, provides a precedent for the study of new drugs for ventricular indications. See p 2649. 
Survival After Open Versus Endovascular Thoracic Aortic Aneurysm Repair in an Observational Study of the Medicare Population

Hybrid Open Endovascular Technique for Aortic Thoracoabdominal Pathologies
Treatment of thoracoabdominal pathologies still remains challenging. Despite higher standards of perioperative care, refinements in operative techniques and the use of several protective adjuncts, including spinal cord protection, hypothermic cardiopulmonary arrest, and selective visceral perfusion, open thoracoabdominal aneurysm repair is still associated with considerable morbidity and mortality rates. An alternative treatment option, especially for patients considered unfit for open conventional repair, can be provided following the hybrid approach. However, ambiguity still characterizes the role of hybrid procedures in thoracoabdominal pathologies treatment, raising a debate for the benefits and risks of the technique. With the intention of summarizing the published experience on this technique and providing an assessment of its safety and efficacy, we undertook a systematic review to identify all published studies and combined the eligible ones in an extensive meta-analysis. This is the most comprehensive meta-analysis to date, including 507 cases with hybrid repair of thoracoabdominal pathologies and providing reliable data concerning the feasibility, the technical success, and the morbidity and mortality rates of this technique. See p 2670.
Acute Coronary Syndrome and Khat Herbal Amphetamine Use: An Observational Report
Chewing the leaves of the plant Catha edulis (khat) likely dates to times of antiquity and may precede the use of coffee. Twenty million people worldwide are believed to be using khat for its stimulant effects. The use of khat was previously confined to East Africa and the Arabian Peninsula. It initially was thought to be of limited concern to Western populations because of its complicated cultivation and distribution systems. However, overnight delivery systems and the immigration of khat chewers contributed to the globalized distribution of khat. Moreover, to make distribution of khat easier and to preserve its efficacy for a longer time, several synthetic forms, including hagigat and graba, were made. Although khat chewing is illegal in the United States, numerous seizures of fresh and dried khat have been made recently. Cathinone, cathine, and norephedrine are the main ingredients of the plant. Cathinone is structurally similar to amphetamine and functionally similar to cocaine and ecstasy (3,4methylenedioxymethamphetamine). Cathinone, the most active khat alkaloid, has been shown to have multiple cardiovascular effects, including increasing heart rate and blood pressure and inducing coronary artery spasm. The present study suggests khat chewers presenting with acute coronary syndrome have fewer cardiovascular risk factors and present late compared with non-khat chewers. This late presentation may be attributed to the analgesic effect of khat. Khat chewers presenting with acute coronary syndrome have increased risk of morbidity and mortality. Increased awareness of endemic practices is paramount in the context of increasing global migration. See p 2681.
Absence of SOCS3 in the Cardiomyocyte Increases Mortality in a gp130-Dependent Manner Accompanied by Contractile Dysfunction and Ventricular Arrhythmias
The serum level of interleukin-6, a ligand for gp130 receptor, is elevated in patients with congestive heart failure (CHF). These elevated levels correspond to worsening functional class, increased hospitalization rates, and poor survival. This suggests that chronic activation of cardiac gp130 signaling may be detrimental to cardiac function. The interleukin-6 family of cytokines is known to induce the expression of SOCS3 through gp130 signaling activation. The
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Original Research Put Into Perspective for the Practicing Clinician Volume 124 Ⅲ Number 24 Ⅲ December 13, 2011 expressed SOCS3 binds to gp130 and inhibits the receptor's downstream signaling. Accordingly, SOCS3 tightly regulates the duration and intensity of gp130 signaling in a classic negative-feedback manner. It has recently been reported that there is a significant decrease in SOCS3 protein or mRNA in human failing hearts. This also implies that chronic gp130 activation and alterations in SOCS3 levels may be involved in the pathogenesis of congestive heart failure. In this study, we sought to determine the role of SOCS3 regulation on gp130 signaling in the heart using cardiac-specific SOCS3 KO mice. We demonstrated that the absence of SOCS3 allows for unregulated, chronic activation of gp130 signaling, leading to contractile dysfunction and ventricular arrhythmias accompanied by abnormal myofilament Ca 2ϩ sensitivity and SR Ca 2ϩ overload. These results demonstrated the importance of homeostatic regulation of cardiac gp130 signaling via SOCS3 and are the first to support the possibility that abnormalities in SOCS3 regulation on cardiac gp130 signaling could be a novel disease mechanism underlying congestive heart failure and fatal arrhythmias in humans as well. See p 2690.
Pak1 as a Novel Therapeutic Target for Antihypertrophic Treatment in the Heart
Heart failure (HF) is one of the most devastating diseases. The lifetime risk of heart failure is 1 in 5 among both men and women. Despite advances in diagnostic and therapeutic technology during past decades, the survival rate after the onset of HF still remains significantly high. There is general agreement that cardiac hypertrophy is a determinant of the clinical course of HF. Therefore, understanding molecular mechanisms of hypertrophic remodeling is a key step in deciphering the pathogenesis of HF. Cardiac hypertrophy is characterized as proliferation-independent cardiomyocyte growth. The signaling programs regulating cell proliferation may be closely related to the programs that control growth of postmitotic adult cardiomyocytes. On the basis of this premise, we identified p21-activated kinase 1 (Pak1), which is important in cell proliferation, as a novel regulator antagonising cardiac hypertrophy. We have also elucidated that Pak1 is an indispensible component of the antihypertrophic signaling, in which Cdc42 (small GTPases) is its upstream activator and JNK (MAP kinase) works downstream of Pak1. Most interestingly, we discovered that FTY720 (a sphingosine-like analog), a Food and Drug Administration-approved drug for treating relapsing multiple sclerosis, is able to limit cardiac hypertrophy of murine hearts. This antihypertrophic effect of FTY720 is likely to function through the activation of Pak1. Overall, our findings provide the evidence to establish Pak1 as a novel antihypertrophic regulator and a potential therapeutic target for the treatment of cardiac hypertrophy and heart failure. See p 2702.
Predictive Value of the High-Sensitivity Troponin T Assay and the Simplified Pulmonary Embolism Severity Index in Hemodynamically Stable Patients With Acute Pulmonary Embolism: A Prospective Validation Study
Early risk stratification of patients with acute pulmonary embolism is critical for therapeutic decision-making. In patients without hemodynamic instability at presentation, laboratory markers of myocardial injury and imaging of right ventricular size and function may indicate an elevated risk, but their clinical utility remains controversial to date. In the present study, we evaluated the predictive value of a new, high-sensitivity troponin T assay (hsTnT) and compared it with a recently developed clinical prognostic score, the simplified Pulmonary Embolism Severity Index (sPESI). In a large multicenter, multinational cohort of 526 patients, the predefined hsTnT cutoff level of 14 pg/mL exhibited a high prognostic sensitivity and negative predictive value, only slightly lower than that of sPESI. Importantly, of 127 patients (24% of the study population) with hsTnT Ͻ14 pg/mL and sPESI of 0, none had an adverse 30-day outcome (negative predictive value, 100%). Thus, hsTnT may be an alternative to sPESI for exclusion of an adverse early outcome, in particular when the variables required for calculation of the clinical score are not immediately available. Moreover, in our study, combination of these 2 simple tools identified low-risk patients with an even higher degree of safety than either test alone. If confirmed by a prospective management trial, this strategy may simplify the management of a significant proportion of patients with pulmonary embolism, and possibly help to reduce treatment costs. See p 2716.
A Key Role for Matrix Metalloproteinases and Neutral Sphingomyelinase-2 in Transplant Vasculopathy Triggered by Anti-HLA Antibody
Despite major advances in clinical organ transplantation, the late outcome of transplanted patients is impaired by chronic rejection, which mainly affects the blood vessels of the transplanted organ, so-called transplant vasculopathy. This pathology is characterized by a progressive neointimal hyperplasia with proliferating smooth muscle cells and secretion of extracellular matrix, leading to arterial stenosis and ischemic failure of the allograft. The mechanism of transplant vasculopathy is only partly understood and involves cellular and humoral immune responses that target the transplanted organ. We wanted to elucidate the manner in which the humoral immune response contributes to transplant vasculopathy. In vitro studies indicated that anti-HLA class I antibodies are mitogenic for human smooth muscle cells through a mechanism that involves matrix metalloproteinases and neutral sphingomyelinase-2. Pharmacological inhibitors of metalloproteinases (batimastat and Ro28-2653) and of neutral sphingomyelinase-2 (GW4869) blocked signaling through these pathways. To explore these findings in vivo, we developed a model for human transplant vasculopathy, consisting of human mesenteric arterial segments grafted into severe combined immunodeficiency/beige mice. Mice injected weekly with monoclonal antibody toward HLA class I developed neointimal thickening of the grafted human arterial segment, whereas mice injected with an irrelevant antibody accepted the graft permanently. Treatment of the animals with Ro28-2653 and GW4869 led to a net reduction of the intimal hyperplasia induced by monoclonal antibody in the human mesenteric artery grafts. These data highlight a crucial role for metalloproteinases and neutral sphingomyelinase-2 in vasculopathy generated by a humoral immune response, opening new therapeutic perspectives for preventing this pathology, in addition to treatment with conventional immunosuppression. See p 2725.
Pathogenic Cycle Between the Endogenous Nitric Oxide Synthase Inhibitor Asymmetrical Dimethylarginine and the Leukocyte-Derived Hemoprotein Myeloperoxidase
The nitric oxide synthase inhibitor asymmetrical dimethylarginine (ADMA) and the leukocyte-derived hemoprotein myeloperoxidase (MPO) are associated with cardiovascular diseases. Activation of monocytes and polymorphonuclear neutrophils with concomitant release of MPO is regulated in a nitric oxide-dependent fashion. The present article describes an ADMA-induced cycle of polymorphonuclear neutrophil activation, MPO release, and subsequent impairment of human dimethylarginine dimethylaminohydrolase1 (hDDAH1) activity. In addition, the data not only highlight so far unrecognized cytokine-like properties of ADMA, but also identify MPO as a regulatory switch for ADMA bioavailability under inflammatory conditions. This finding suggests that understanding the underlying mechanisms of the ADMA/ MPO interaction may open a new avenue for treatment of cardiovascular disease. See p 2735.
